吸入曲前列尼尔治疗特发性肺纤维化
这项3期双盲试验将593例特发性肺纤维化患者随机分配至吸入曲前列尼尔组(298例)或安慰剂组(295例),每日四次、每次12吸,疗程52周。主要终点第52周FVC绝对值较基线变化:曲前列尼尔组中位下降49.9 ml(95%CI -79.2至-19.5),安慰剂组下降136.4 ml(95%CI -172.5至-104.0),组间差异95.6 ml(95%CI 52.2至139.0;P<0.001)。临床恶化曲前列尼尔组81例(27.2%)vs 安慰剂组115例(39.0%),HR 0.71(95%CI 0.53至0.95;P=0.02)。IPF急性加重时间两组无实质性差异,因此未对后续次要终点进一步推断。最常见不良事件为咳嗽(曲前列尼尔组48.3% vs 安慰剂组24.1%),因不良事件停药比例较高。
要点
- 特发性肺纤维化患者吸入曲前列尼尔每日四次、每次12吸共52周,第52周FVC中位下降49.9 ml,安慰剂组下降136.4 ml,组间差异95.6 ml(95%CI 52.2至139.0;P<0.001)。
- 临床恶化曲前列尼尔组27.2%(81例)vs 安慰剂组39.0%(115例),HR 0.71(95%CI 0.53至0.95;P=0.02)。
- IPF急性加重时间两组无实质性差异,未对后续次要终点(死亡、FVC占预计值百分比变化、生活质量、DLCO变化)进一步推断。
- 最常见不良事件为咳嗽,曲前列尼尔组48.3% vs 安慰剂组24.1%;停药率曲前列尼尔组33.6% vs 安慰剂组24.7%,约半数因不良事件停药。
- 基线时75.4%患者正在接受背景抗纤维化治疗,平均年龄71.7岁,男性80.1%,平均FVC为预计值的76.8%。
适用人群与场景
- 特发性肺纤维化患者,平均年龄71.7岁,80.1%为男性,基线平均FVC为预计值的76.8%,75.4%正在接受背景抗纤维化治疗。
- 随机分配后至少接受一剂曲前列尼尔(298例)或安慰剂(295例)的患者;完成52周试验评估者共463例(曲前列尼尔组224例,安慰剂组239例)。
处置流程与药物剂量
- 吸入曲前列尼尔每日四次、每次12吸,疗程52周;对照为安慰剂每日四次、每次12吸。
- 曲前列尼尔组33.6%停药、安慰剂组24.7%停药,约半数停药者以不良事件为主要原因。
研究设计与关键结果
- 3期双盲随机对照试验,593例特发性肺纤维化患者随机接受吸入曲前列尼尔(298例)或安慰剂(295例),每日四次、每次12吸,疗程52周。
- 主要终点第52周FVC绝对值较基线变化:曲前列尼尔组中位下降49.9 ml(95%CI -79.2至-19.5)vs 安慰剂组下降136.4 ml(95%CI -172.5至-104.0),组间差异95.6 ml(95%CI 52.2至139.0;P<0.001)。
- 临床恶化:曲前列尼尔组81例(27.2%)vs 安慰剂组115例(39.0%),HR 0.71(95%CI 0.53至0.95;P=0.02)。
- IPF急性加重时间两组无实质性差异,未对后续次要终点(第52周死亡、FVC占预计值百分比变化、生活质量、DLCO变化)进一步推断。
- 最常见不良事件为咳嗽:曲前列尼尔组48.3% vs 安慰剂组24.1%;停药率曲前列尼尔组33.6% vs 安慰剂组24.7%,约半数因不良事件停药。
证据类型、等级与局限
- 证据类型:3期双盲随机对照试验(TETON-2,NCT05255991),由United Therapeutics资助。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在特发性肺纤维化患者中,吸入曲前列尼尔每日四次、每次12吸共52周,与安慰剂相比FVC下降更小、临床恶化事件更少,但咳嗽更常见、停药率更高。
- IPF急性加重时间两组无实质性差异,因此未对死亡、FVC占预计值百分比变化、生活质量和DLCO变化等后续次要终点作进一步推断。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Preclinical data indicate that inhaled treprostinil may be useful for the treatment of idiopathic pulmonary fibrosis (IPF) through an antifibrotic mechanism, a premise that is supported by clinical observation.
METHODS: In this phase 3, double-blind trial, we randomly assigned patients with IPF to receive inhaled treprostinil or placebo (12 breaths four times daily) over a period of 52 weeks. The primary end point was the change from baseline in the absolute forced vital capacity (FVC) at week 52. Secondary end points, which were analyzed in a prespecified order to control for multiplicity, were clinical worsening and acute exacerbation of IPF (each assessed in a time-to-event analysis), death by week 52, and the change from baseline in the percentage of predicted FVC, quality of life, and the diffusing capacity of the lungs for carbon monoxide by week 52. Safety was also assessed.
RESULTS: A total of 593 patients underwent randomization and received at least one dose of treprostinil (298 patients) or placebo (295 patients). Of these, 463 patients (224 in the treprostinil group and 239 in the placebo group) completed the trial assessments through week 52. The mean age of the patients was 71.7 years, 80.1% were men, the mean FVC at baseline was 76.8%, and 75.4% of the patients were receiving background antifibrotic therapy. The median change in FVC at week 52 was -49.9 ml (95% confidence interval [CI], -79.2 to -19.5) in the treprostinil group and -136.4 ml (95% CI, -172.5 to -104.0) in the placebo group; the between-group difference in the change in FVC was 95.6 ml (95% CI, 52.2 to 139.0; P<0.001). Clinical worsening occurred in 81 patients (27.2%) in the treprostinil group and 115 patients (39.0%) in the placebo group (hazard ratio, 0.71; 95% CI, 0.53 to 0.95; P = 0.02). No substantial between-group difference in the time to IPF exacerbation was observed, and so no further inferences with regard to subsequent secondary end points were made. The most common adverse event was cough, reported in 48.3% of the patients in the treprostinil group and 24.1% of those in the placebo group. Discontinuation of treprostinil or placebo occurred in 33.6% and 24.7%, respectively, with approximately half these patients citing adverse events as the primary reason for discontinuation.
CONCLUSIONS: In patients with IPF, inhaled treprostinil was associated with a smaller decline in FVC and fewer clinical-worsening events than placebo over a period of 52 weeks. (Funded by United Therapeutics; TETON-2 ClinicalTrials.gov number, NCT05255991.).
参考来源
- Nathan SD, Smith P, Deng C, et al. Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis. N Engl J Med. 2026. PMID: 41812190. doi:10.1056/NEJMoa2512911
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。